Last reviewed · How we verify

NCT03230162

Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment

Status unknown Phase 3 Last updated 26 July 2017
What this trial tests

Phase 3 trial testing Sildenafil in Fetal Growth Abnormality in 100 participants. Status unknown.

Timeline
1 June 2017
Primary endpoint
1 May 2018
1 May 2018

Quick facts

Lead sponsorAin Shams University
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 June 2017
Primary completion1 May 2018
Estimated completion1 May 2018
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 20 to 35, female only, with Fetal Growth Abnormality or Fetal Growth Restriction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

comparing the effect of using sildenafil citrate and LMWH in treatment of cases of IUGR due to placental insufficiency

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sildenafil

Trials testing the same drug.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03230162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing